{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.76","value":"-14.4"},{"groupId":"OG001","spread":"33.60","value":"-13.8"},{"groupId":"OG002","spread":"29.32","value":"-13.4"}]}],"title":"Cycle 4 - approximately Month 4 (n=120,127,129)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.18","value":"-17.8"},{"groupId":"OG001","spread":"33.45","value":"-16.5"},{"groupId":"OG002","spread":"33.49","value":"-11.5"}]}],"title":"Cycle 7 - approximately Month 7 (n=100,112,113)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.78","value":"-17.2"},{"groupId":"OG001","spread":"35.30","value":"-15.6"},{"groupId":"OG002","spread":"31.71","value":"-9.8"}]}],"title":"Cycle 10 - approximately Month 10 (n=88,95,97)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.48","value":"-13.7"},{"groupId":"OG001","spread":"33.28","value":"-14.9"},{"groupId":"OG002","spread":"27.46","value":"-12.1"}]}],"title":"Cycle 13 - approximately Month 13 (n=74,74,83)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.92","value":"-20.3"},{"groupId":"OG001","spread":"33.00","value":"-11.0"},{"groupId":"OG002","spread":"29.96","value":"-12.2"}]}],"title":"Cycle 16 - approximately Month 16 (n=64,53,63)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}